Cargando…

Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518699/ https://www.ncbi.nlm.nih.gov/pubmed/37748804 http://dx.doi.org/10.1136/bmj.p2193

Ejemplares similares

Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
por: Mohraz, Minoo, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
por: Mohraz, Minoo, et al.
Publicado: (2022)

Correction: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
Publicado: (2022)

Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
por: Salehi, Mohammadreza, et al.
Publicado: (2022)

The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies
por: Shafaati, Maryam, et al.
Publicado: (2023)

Bivs, Space and ‘In’
por: Mac Cumhaill, Clare
Publicado: (2020)

Characterization of BIV Env core: Implication for mechanism of BIV-mediated cell fusion
por: Li, Shu, et al.
Publicado: (2005)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
por: Zhu, Fengcai, et al.
Publicado: (2023)

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials
por: Ozdarendeli, Aykut, et al.
Publicado: (2023)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Randomised Double-blind Placebo-Controlled Multicentre Trial for the Effects of Yokukansan in Smokers with Depressive Tendencies
por: Komiyama, Maki, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
por: Zhang, Yanjun, et al.
Publicado: (2021)

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
por: Schneider, Martina, et al.
Publicado: (2023)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

MULTICENTRIC, PLACEBO-CONTROLLED, RANDOMISED DOUBLE-BLIND EVALUATION OF A NEW HERBAL CREAM IN VAGIAL INFECTIONS
por: Rani, P. Usha, et al.
Publicado: (1995)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
por: Wang, Yeming, et al.
Publicado: (2020)

Nitroglycerin for treatment of retained placenta: A randomised, placebo-controlled, multicentre, double-blind trial in the UK
por: Denison, Fiona C., et al.
Publicado: (2019)

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
por: Fennell, Dean A, et al.
Publicado: (2021)

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
por: Singh, Dave, et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
por: Wu, Zhiwei, et al.
Publicado: (2021)

Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM)
por: Erdal, Ane, et al.
Publicado: (2018)

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2020)

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
por: Gholami, Fatemeh, et al.
Publicado: (2023)

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
por: Marconi, Vincent C, et al.
Publicado: (2021)

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
por: Thwaites, Guy E, et al.
Publicado: (2018)

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
Publicado: (2013)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
por: Drayson, Mark T, et al.
Publicado: (2019)

High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial
por: Mitsui, Jun, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
por: Guo, Wanshen, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial
por: Ansarifar, Akram, et al.
Publicado: (2023)

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chappell, Keith J, et al.
Publicado: (2021)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chen, Gui-Ling, et al.
Publicado: (2022)

Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial
por: O’Hara, James, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6hahqmdnq5bbsndm48m1cvbkp